Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Erratum to: ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.

Gelsomino L, Gu G, Rechoum Y, Beyer AR, Pejerrey SM, Tsimelzon A, Wang T, Huffman K, Ludlow A, Andò S, Fuqua SAW.

Breast Cancer Res Treat. 2017 Jun;163(3):639-640. doi: 10.1007/s10549-017-4250-4. No abstract available.

PMID:
28439737
2.

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.

Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, Shea M, Nardone A, De Angelis C, Heiser LM, Anur P, Wang N, Grasso CS, Spellman PT, Griffith OL, Tsimelzon A, Gutierrez C, Huang S, Edwards DP, Trivedi MV, Rimawi MF, Lopez-Terrada D, Hilsenbeck SG, Gray JW, Brown M, Osborne CK, Schiff R.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):E6600-E6609. Epub 2016 Oct 6.

3.

Research Resource: A Reference Transcriptome for Constitutive Androstane Receptor and Pregnane X Receptor Xenobiotic Signaling.

Ochsner SA, Tsimelzon A, Dong J, Coarfa C, McKenna NJ.

Mol Endocrinol. 2016 Aug;30(8):937-48. doi: 10.1210/me.2016-1095. Epub 2016 Jul 13.

4.

Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion.

Mazumdar A, Poage GM, Shepherd J, Tsimelzon A, Hartman ZC, Den Hollander P, Hill J, Zhang Y, Chang J, Hilsenbeck SG, Fuqua S, Kent Osborne C, Mills GB, Brown PH.

Breast Cancer Res Treat. 2016 Aug;158(3):441-54. doi: 10.1007/s10549-016-3892-y. Epub 2016 Jul 8.

5.

ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.

Gelsomino L, Gu G, Rechoum Y, Beyer AR, Pejerrey SM, Tsimelzon A, Wang T, Huffman K, Ludlow A, Andò S, Fuqua SAW.

Breast Cancer Res Treat. 2016 Jun;157(2):253-265. doi: 10.1007/s10549-016-3829-5. Epub 2016 May 13. Erratum in: Breast Cancer Res Treat. 2017 Jun;163(3):639-640.

6.

Research Resource: Roles for Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CaMKK2) in Systems Metabolism.

Marcelo KL, Ribar T, Means CR, Tsimelzon A, Stevens RD, Ilkayeva O, Bain JR, Hilsenbeck SG, Newgard CB, Means AR, York B.

Mol Endocrinol. 2016 May;30(5):557-72. doi: 10.1210/me.2016-1021. Epub 2016 Mar 22.

7.

Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival.

den Hollander P, Rawls K, Tsimelzon A, Shepherd J, Mazumdar A, Hill J, Fuqua SA, Chang JC, Osborne CK, Hilsenbeck SG, Mills GB, Brown PH.

Cancer Res. 2016 Apr 1;76(7):1942-53. doi: 10.1158/0008-5472.CAN-14-0673. Epub 2016 Feb 26.

8.

The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression.

Shepherd JH, Uray IP, Mazumdar A, Tsimelzon A, Savage M, Hilsenbeck SG, Brown PH.

Oncotarget. 2016 Mar 15;7(11):13106-21. doi: 10.18632/oncotarget.7437.

9.

HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes.

Nikolai BC, Lanz RB, York B, Dasgupta S, Mitsiades N, Creighton CJ, Tsimelzon A, Hilsenbeck SG, Lonard DM, Smith CL, O'Malley BW.

Cancer Res. 2016 Mar 15;76(6):1463-75. doi: 10.1158/0008-5472.CAN-15-2383. Epub 2016 Feb 1.

10.

Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.

Ciupek A, Rechoum Y, Gu G, Gelsomino L, Beyer AR, Brusco L, Covington KR, Tsimelzon A, Fuqua SA.

Breast Cancer Res Treat. 2015 Nov;154(2):225-37. doi: 10.1007/s10549-015-3609-7. Epub 2015 Oct 20.

11.

CAPER is vital for energy and redox homeostasis by integrating glucose-induced mitochondrial functions via ERR-α-Gabpa and stress-induced adaptive responses via NF-κB-cMYC.

Kang YK, Putluri N, Maity S, Tsimelzon A, Ilkayeva O, Mo Q, Lonard D, Michailidis G, Sreekumar A, Newgard CB, Wang M, Tsai SY, Tsai MJ, O'Malley BW.

PLoS Genet. 2015 Apr 1;11(4):e1005116. doi: 10.1371/journal.pgen.1005116. eCollection 2015 Apr. Erratum in: PLoS Genet. 2015 Jun;11(6):e1005316.

12.

Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer.

Zhang M, Tsimelzon A, Chang CH, Fan C, Wolff A, Perou CM, Hilsenbeck SG, Rosen JM.

Cancer Discov. 2015 May;5(5):520-33. doi: 10.1158/2159-8290.CD-14-1101. Epub 2015 Mar 3.

13.

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.

Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, Savage MI, Osborne CK, Hilsenbeck SG, Chang JC, Mills GB, Lau CC, Brown PH.

Clin Cancer Res. 2015 Apr 1;21(7):1688-98. doi: 10.1158/1078-0432.CCR-14-0432. Epub 2014 Sep 10.

14.

Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer.

Covington KR, Brusco L, Barone I, Tsimelzon A, Selever J, Corona-Rodriguez A, Brown P, Kumar R, Hilsenbeck SG, Fuqua SA.

Breast Cancer Res Treat. 2013 Oct;141(3):375-384. Epub 2013 Sep 28.

15.

A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.

Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua SW, Contreras A, Gutierrez C, Huang J, Mao S, Pavlick AC, Froehlich AM, Wu MF, Tsimelzon A, Hilsenbeck SG, Chen ES, Zuloaga P, Shaw CA, Rimawi MF, Perou CM, Mills GB, Chang JC, Lewis MT.

Cancer Res. 2013 Aug 1;73(15):4885-97. doi: 10.1158/0008-5472.CAN-12-4081. Epub 2013 Jun 4.

16.

Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8.

Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck SG, Mills GB, Brown PH.

Cancer Res. 2013 Jun 1;73(11):3470-80. doi: 10.1158/0008-5472.CAN-12-4524-T. Epub 2013 Apr 30.

17.

Research resource: tissue- and pathway-specific metabolomic profiles of the steroid receptor coactivator (SRC) family.

York B, Sagen JV, Tsimelzon A, Louet JF, Chopra AR, Reineke EL, Zhou S, Stevens RD, Wenner BR, Ilkayeva O, Bain JR, Xu J, Hilsenbeck SG, Newgard CB, O'Malley BW.

Mol Endocrinol. 2013 Feb;27(2):366-80. doi: 10.1210/me.2012-1324. Epub 2013 Jan 11.

18.

SRC-2 coactivator deficiency decreases functional reserve in response to pressure overload of mouse heart.

Reineke EL, York B, Stashi E, Chen X, Tsimelzon A, Xu J, Newgard CB, Taffet GE, Taegtmeyer H, Entman ML, O'Malley BW.

PLoS One. 2012;7(12):e53395. doi: 10.1371/journal.pone.0053395. Epub 2012 Dec 31.

19.

Ablation of steroid receptor coactivator-3 resembles the human CACT metabolic myopathy.

York B, Reineke EL, Sagen JV, Nikolai BC, Zhou S, Louet JF, Chopra AR, Chen X, Reed G, Noebels J, Adesina AM, Yu H, Wong LJ, Tsimelzon A, Hilsenbeck S, Stevens RD, Wenner BR, Ilkayeva O, Xu J, Newgard CB, O'Malley BW.

Cell Metab. 2012 May 2;15(5):752-63. doi: 10.1016/j.cmet.2012.03.020.

20.

Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells.

Selever J, Gu G, Lewis MT, Beyer A, Herynk MH, Covington KR, Tsimelzon A, Dontu G, Provost P, Di Pietro A, Boumendjel A, Albain K, Miele L, Weiss H, Barone I, Ando S, Fuqua SA.

Clin Cancer Res. 2011 Oct 15;17(20):6510-21. doi: 10.1158/1078-0432.CCR-11-1403. Epub 2011 Aug 30.

21.

A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.

Massarweh S, Tham YL, Huang J, Sexton K, Weiss H, Tsimelzon A, Beyer A, Rimawi M, Cai WY, Hilsenbeck S, Fuqua S, Elledge R.

Breast Cancer Res Treat. 2011 Oct;129(3):819-27. doi: 10.1007/s10549-011-1679-8. Epub 2011 Jul 27.

22.

A gene transcription signature of obesity in breast cancer.

Creighton CJ, Sada YH, Zhang Y, Tsimelzon A, Wong H, Dave B, Landis MD, Bear HD, Rodriguez A, Chang JC.

Breast Cancer Res Treat. 2012 Apr;132(3):993-1000. doi: 10.1007/s10549-011-1595-y. Epub 2011 Jul 13.

PMID:
21750966
23.

Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles.

Loudin MG, Wang J, Leung HC, Gurusiddappa S, Meyer J, Condos G, Morrison D, Tsimelzon A, Devidas M, Heerema NA, Carroll AJ, Plon SE, Hunger SP, Basso G, Pession A, Bhojwani D, Carroll WL, Rabin KR.

Leukemia. 2011 Oct;25(10):1555-63. doi: 10.1038/leu.2011.128. Epub 2011 Jun 7.

24.

Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth.

Casa AJ, Potter AS, Malik S, Lazard Z, Kuiatse I, Kim HT, Tsimelzon A, Creighton CJ, Hilsenbeck SG, Brown PH, Oesterreich S, Lee AV.

Breast Cancer Res Treat. 2012 Feb;132(1):61-73. doi: 10.1007/s10549-011-1540-0. Epub 2011 May 4.

25.

Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.

Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Andò S, Fuqua SA.

J Natl Cancer Inst. 2011 Apr 6;103(7):538-52. doi: 10.1093/jnci/djr058. Epub 2011 Mar 29.

26.

High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy.

Litzenburger BC, Creighton CJ, Tsimelzon A, Chan BT, Hilsenbeck SG, Wang T, Carboni JM, Gottardis MM, Huang F, Chang JC, Lewis MT, Rimawi MF, Lee AV.

Clin Cancer Res. 2011 Apr 15;17(8):2314-27. doi: 10.1158/1078-0432.CCR-10-1903. Epub 2010 Dec 22.

27.

Research resource: expression profiling reveals unexpected targets and functions of the human steroid receptor RNA activator (SRA) gene.

Foulds CE, Tsimelzon A, Long W, Le A, Tsai SY, Tsai MJ, O'Malley BW.

Mol Endocrinol. 2010 May;24(5):1090-105. doi: 10.1210/me.2009-0427. Epub 2010 Mar 10.

28.

Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity.

Barone I, Iacopetta D, Covington KR, Cui Y, Tsimelzon A, Beyer A, Andò S, Fuqua SA.

Oncogene. 2010 Apr 22;29(16):2404-14. doi: 10.1038/onc.2009.520. Epub 2010 Jan 25.

29.

SAFB1 mediates repression of immune regulators and apoptotic genes in breast cancer cells.

Hammerich-Hille S, Kaipparettu BA, Tsimelzon A, Creighton CJ, Jiang S, Polo JM, Melnick A, Meyer R, Oesterreich S.

J Biol Chem. 2010 Feb 5;285(6):3608-16. doi: 10.1074/jbc.M109.066431. Epub 2009 Nov 9.

30.

Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer.

Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A, Quackenbush J, Hilsenbeck S, Chang J, Brown P.

Clin Cancer Res. 2009 Oct 15;15(20):6327-40. doi: 10.1158/1078-0432.CCR-09-1107. Epub 2009 Oct 6.

31.

Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells.

De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, Weigel NL, Herynk MH, Tsimelzon A, Lewis MT, Chamness GC, Hilsenbeck SG, Andò S, Fuqua SA.

Breast Cancer Res Treat. 2010 May;121(1):1-11. doi: 10.1007/s10549-009-0436-8. Epub 2009 Jun 17.

32.

Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density.

Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin A, Chang JC.

Breast Cancer Res Treat. 2010 Jan;119(2):305-14. doi: 10.1007/s10549-009-0350-0. Epub 2009 Feb 25.

33.

Prevention of trauma/hemorrhagic shock-induced lung apoptosis by IL-6-mediated activation of Stat3.

Moran A, Tsimelzon AI, Mastrangelo MA, Wu Y, Yu B, Hilsenbeck SG, Poli V, Tweardy DJ.

Clin Transl Sci. 2009 Feb;2(1):41-9. doi: 10.1111/j.1752-8062.2008.00076.x.

34.

Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.

Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R.

Cancer Res. 2008 Sep 15;68(18):7493-501. doi: 10.1158/0008-5472.CAN-08-1404.

35.

Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis.

Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Lee AV.

J Clin Oncol. 2008 Sep 1;26(25):4078-85. doi: 10.1200/JCO.2007.13.4429.

36.

Identification of tumor-initiating cells in a p53-null mouse model of breast cancer.

Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D, Medina D, Tsimelzon A, Hilsenbeck S, Green JE, Michalowska AM, Rosen JM.

Cancer Res. 2008 Jun 15;68(12):4674-82. doi: 10.1158/0008-5472.CAN-07-6353.

37.

Inhibition of mammary tumorigenesis by estrogen and progesterone in genetically engineered mice.

Medina D, Kittrell FS, Tsimelzon A, Fuqua SA.

Ernst Schering Found Symp Proc. 2007;(1):109-26. Review.

PMID:
18540570
38.

Prevention of hypovolemic circulatory collapse by IL-6 activated Stat3.

Alten JA, Moran A, Tsimelzon AI, Mastrangelo MA, Hilsenbeck SG, Poli V, Tweardy DJ.

PLoS One. 2008 Feb 13;3(2):e1605. doi: 10.1371/journal.pone.0001605. Erratum in: PLoS ONE. 2008;3(6). doi: 10.1371/annotation/c13f83c0-dc7e-4e5f-9b85-2bd041d3a6d8.

39.

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.

Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R.

Cancer Res. 2008 Feb 1;68(3):826-33. doi: 10.1158/0008-5472.CAN-07-2707.

40.

Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution.

Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, Mohsin SK, O'Connell P, Tsimelzon A, Medina D.

Clin Cancer Res. 2008 Jan 15;14(2):370-8. doi: 10.1158/1078-0432.CCR-07-1127.

41.
42.

Alterations of gene expression in the development of early hyperplastic precursors of breast cancer.

Lee S, Medina D, Tsimelzon A, Mohsin SK, Mao S, Wu Y, Allred DC.

Am J Pathol. 2007 Jul;171(1):252-62.

43.

Wnt-1 is dominant over neu in specifying mammary tumor expression profiles.

Huang S, Podsypanina K, Chen Y, Cai W, Tsimelzon A, Hilsenbeck S, Li Y.

Technol Cancer Res Treat. 2006 Dec;5(6):565-71.

PMID:
17121432
44.

Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype.

Nguyen DM, Sam K, Tsimelzon A, Li X, Wong H, Mohsin S, Clark GM, Hilsenbeck SG, Elledge RM, Allred DC, O'Connell P, Chang JC.

Clin Cancer Res. 2006 Sep 1;12(17):5047-54.

45.

Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance.

Cui Y, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T, Horii A, Zhang ZY, Nicholson RI, Fuqua SA.

Cancer Res. 2006 Jun 1;66(11):5950-9.

46.

Radical [n + 1] annulations with sulfur dioxide.

Tsimelzon A, Braslau R.

J Org Chem. 2005 Dec 23;70(26):10854-9.

PMID:
16356008
47.

Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance.

Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, Powles T, Hilsenbeck S, Wong H, Osborne CK, O'Connell P, Chang JC.

Breast Cancer Res Treat. 2006 Feb;95(3):229-33.

PMID:
16322899
48.

Transcriptional profiling of mammary gland side population cells.

Behbod F, Xian W, Shaw CA, Hilsenbeck SG, Tsimelzon A, Rosen JM.

Stem Cells. 2006 Apr;24(4):1065-74. Epub 2005 Nov 10.

49.

Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients.

Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, Lewis MT, Wong H, O'Connell P.

J Clin Oncol. 2005 Feb 20;23(6):1169-77.

PMID:
15718313
50.

Hazard rates of recurrence following diagnosis of primary breast cancer.

Jatoi I, Tsimelzon A, Weiss H, Clark GM, Hilsenbeck SG.

Breast Cancer Res Treat. 2005 Jan;89(2):173-8.

PMID:
15692760

Supplemental Content

Loading ...
Support Center